2024-514532-24-00已完成1 期
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (7)
Loading locations...
相似试验
招募中
不适用
A study in people with advanced cancer to test how well different doses of BI 770371 alone or in combination with ezabenlimab are toleratedjRCT2031220031Nippon Boehringer Ingelheim Co., Ltd12
招募中
1 期
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helpsMelanoma2025-522045-21-00Boehringer Ingelheim International GmbH13
已完成
不适用
Investigation for advanced cancer patients' treatment preferences and their end of life careadvanced cancerJPRN-UMIN000026436agoya City University400
进行中（未招募）
1 期
A study for people with advanced colorectal cancer who have been treated with a specific chemotherapy regimen (Bevacizumab, Oxaliplatin, and a Fluoropyrimidine) which was ineffective in stopping the spread of the colorectal cancer. Study participants will receive a different chemotherapy regimen (Irinotecan, Folinic Acid, and 5-Fluorouracil) and be randomly and unknowingly assigned to also receive the study drug (ramucirimab) or a non-active compound (placebo).Metastatic Colorectal CancerMedDRA version: 17.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864EUCTR2010-021037-32-DEEli Lilly and Company Limited, Indianapolis1,050
招募中
1 期
A Phase 1 Study of HDM2017 in Advanced Solid TumorsNCT07274085Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.96